Peel Therapeutics Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $9.3M
Latest Deal Amount

Peel Therapeutics General Information


Developer of a cancer care platform designed to deliver anti-cancer protein nano-particles. The company's cancer care platform delivers anti-cancer nano-particles which regulates cellular response to environmental stresses by stimulating transcription of genes involved in cell cycle arrests, cell death and metabolisms, enabling physicians to treat and cure cancer in humans.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Social/Platform Software
Drug Discovery
Primary Office
  • 1387 South Ambassador Way
  • Salt Lake City, UT 84108
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Peel Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Angel (individual) 05-Feb-2019 $9.3M 00.00 Completed Startup
To view Peel Therapeutics’s complete valuation and funding history, request access »

Peel Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
James Levison Chief Financial Officer
Lisa Abegglen Ph.D Project Manager & Scientist
Joshua Schiffman MD Co-Founder
To view Peel Therapeutics’s complete executive team members history, request access »